1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Calando Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Calando Pharmaceuticals, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 28 pages

Calando Pharmaceuticals, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Calando Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Calando Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Calando Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Calando Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Calando Pharmaceuticals, Inc. - Brief Calando Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Calando Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Calando Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Calando Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Calando Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Calando Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Calando Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Calando Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Calando Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Calando Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Calando Pharmaceuticals, Inc. Snapshot 4
Calando Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Calando Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Calando Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Calando Pharmaceuticals, Inc. - Pipeline Products Glance 9
Calando Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Calando Pharmaceuticals, Inc. - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Calando Pharmaceuticals, Inc. - Drug Profiles 11
CALAA-01 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
CALAA-02 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Calando Pharmaceuticals, Inc. - Pipeline Analysis 14
Calando Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 14
Calando Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 15
Calando Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 16
Calando Pharmaceuticals, Inc. - Recent Pipeline Updates 17
Calando Pharmaceuticals, Inc. - Locations And Subsidiaries 18
Head Office 18
Financial Deals Landscape 19
Calando Pharmaceuticals, Inc., Deals Summary 19
Calando Pharmaceuticals, Inc., Pharmaceuticals and Healthcare, Deal Details 20
Merger 20
Calando Pharma Merges With Insert Therapeutics 20
Licensing Agreements 21
Cerulean Pharma Enters Into Licensing Agreement With Calando Pharma 21
Alnylam Pharma Enters Into Licensing Agreement With Calando Pharma 23
Debt Offering 24
Calando Pharma Completes Private Placement For US$2.7 Million 24
Acquisition 25
Arrowhead Research Acquires Additional Stake In Calando Pharma 25
Appendix 27
Methodology 27
Coverage 27
Secondary Research 27
Primary Research 27
Expert Panel Validation 27
Contact Us 28
Disclaimer 28



List of Tables

Calando Pharmaceuticals, Inc., Key Information 4
Calando Pharmaceuticals, Inc., Key Facts 4
Calando Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Calando Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Calando Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Calando Pharmaceuticals, Inc. - Phase I, 2013 9
Calando Pharmaceuticals, Inc. - Pre-Clinical, 2013 10
Calando Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 14
Calando Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 15
Calando Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 16
Calando Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 17
Calando Pharmaceuticals, Inc., Deals Summary 19
Calando Pharma Merges With Insert Therapeutics 20
Cerulean Pharma Enters Into Licensing Agreement With Calando Pharma 21
Alnylam Pharma Enters Into Licensing Agreement With Calando Pharma 23
Calando Pharma Completes Private Placement For US$2.7 Million 24
Arrowhead Research Acquires Additional Stake In Calando Pharma 25



List of Figures

Calando Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Calando Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Calando Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Calando Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 15
Calando Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.